Congratulations to REVA Medical CEO and former Life Science Partner placement Reggie Groves on her feature in this week’s San Diego Business Journal!
Former President and Chief Executive Officer of Vascular Pathways
Life Science Partner has recruited Bill Bold, former CEO of Vascular Pathways and senior medical device leader, to become Chief Executive Officer for Vestagen, an innovator in the development of Active Barrier fabrics and protection technology to protect the healthcare worker.
Prior to joining Vestagen, Bold turned around Vascular Pathways with product innovation and commercialization and sold the company to CR Bard for its best-in-class portfolio of peripheral vascular access technologies. “Bold is an articulate, strategic and a strong leader who recruits world-class teams to early-stage companies,” stated Tom Callaway, MD, Founder and President of Life Science Partner and Venture Partner at HealthQuest Capital, an investor in the company.
“With a track record for delivering a strong return on investment in fundraising with venture capital and private equity, Bold has the experience to lead Vestagen’s growth and profitability within the healthcare industry,” noted Callaway.
Prior to joining Vascular Pathways, Bold held executive leadership roles for both early stage and corporate divisions of medical device companies such as Access Scientific, Venetec, Medibuy and CR Bard.
Bold earned a Bachelor of Science Degree in Marketing from West Chester University.
Former Medical Director, Global Medical Marketing, ConvaTec
Life Science Partner recruited Michel Hermans, MD, a surgically trained medical affairs executive to become Chief Medical Officer for TissueTech.
Hermans joins TissueTech after serving as a biopharma consultant for his own firm and Medical Director, Global Medical Marketing for ConvaTech. Previously, Hermans served served as Medical Director for Ortec where he successfully led the new clinical trials for the commercialization of OrCel globally.
TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, orthopedic reconstructive surgeries and wound care markets.
TissueTech offers its portfolio products through its commercial entities: BioTissue, Inc., the industry leader in regenerative tissue therapies for ocular surface diseases and disorders, and Amniox Medical, a leading technology provider to the orthopedic and wound care markets.
“Hermans has the direct clinical trials management experience that leads to the approval of biologics in the BLA regulatory pathway – and brings that background to TissueTech’s clinical and regulatory strategy,” states Tom Callaway, MD, Founder and President of Life Science Partner. “In addition, as a specialist in treating burn patients, he brings real-life clinical experience to the company.”
Hermans earned his Medical Degree from the University of Groningen in the Netherlands and completed his training in general surgery, burn and trauma care from the Rode Kruis Ziekenhuis and Burn Center in Beverwijk, Netherlands.
Former Senior Director, Global Safety Officer at The Medicines Company
Life Science Partner recruited Yanshan Ma, MD, PhD, to become Senior Director, Medical Safety Physician, Internal Medicine and Infectious Diseases for Allergan. In her new role Dr. Ma will be responsible for the group’s safety strategy, pharmacovigilance and medical risk management.
Dr. Ma joins Allergan after leading a cross-functional safety management team at The Medicines Company where she was responsible for ensuring accurate safety evaluation and signal detection. She’s been a key member in the growth of The Medicines Company.
“Dr. Ma has hands-on leadership experience of both small groups and matrix organizations of physicians and safety scientists,” commented Tom Callaway, MD, Founder and President of Life Science Partner. “She has the work ethic and pharmacovigilence knowledge that will fit nicely with the entrepreneurial environment of Allergan.”
Dr. Ma earned her PhD in Biochemistry from East Tennessee State University’s James E. Quillen College of Medicine and her MD from Sun Yat-sen University of Medical Sciences in China.